Q3 2022 Organon & Co Earnings Call
Proud to have achieved this milestone.
It is Oregon on first molecular entity to enter this phase and signifies our dedication to developing novel alternative therapies for patients suffering from endometriosis.
Endometriosis is among our highest priority areas of focus it's a common and chronic condition that affects up to one in 10 women of reproductive age and yet despite increasing awareness of this condition. There are currently no long term approved treatment options.
The compound we are studying is different than currently available treatments because of its potential ability to act locally in the target tissues without impacting systemic hormone levels.
This potentially selective activity allows for its evaluation as a long term treatment option for endometriosis. We are proud to be moving forward with this research in the hopes of addressing the significant unmet need.
Turning to Biosimilars, we continue to have solid uptake of <unk> in the U S.
While the phasing of tenders will show up in quarterly results year to date. This business is developing or delivering double digit growth and we expect results for the full year to demonstrate double digit growth as well.
Our next Biosimilar launch will be mid next year with our launch of had Lima in the U S.
There are other biosimilars launching along with us in July , but here's why we think it will be successful.
We believe that Biosimilars that will be best positioned to succeed or those that share the same attributes as the originator of humira.
That includes the option for a high concentration citrate free formulation and a low concentration formulation and we expect to have both at launch. We also believe that real world evidence and experienced in other markets as important for provider uptake and product confidence our collaborator Samsung <unk> has data from.
Their launch of <unk> Lima, and to you and we have data from our own launches in Canada, and Australia, and finally, our pen design.
<unk> is an expert in device design and manufacturing, we believe our pen design can deliver a frictionless experience for patients transitioning from Humira and we think will be a true differentiator among our other offerings.
And before I turn the discussion over to Matt what should go not under which should go which should not go under appreciated on slide six is our established brands business.
That franchise currently represents about two thirds of our overall business. The portfolio continues to demonstrate the sustainability and untapped potential of these brands and generate significant free cash flow.
Year to date established brands has delivered 6% growth on a constant currency basis.
Given its strong year to date performance, we expect the established brands franchise to deliver modest revenue growth for the full year 2022.
Even with some expected impact from volume based procurement in China in the fourth quarter.
Our strategic owners of this business, we are staying nimble so that we can capitalize on dislocations in local markets like competitor stock outs.
Our policy and market access teams have worked to minimize price erosions, where possible and we have been strategic about extracting value from longstanding brands with planned lifecycle management activities.
With these initiatives and programs. We believe we can manage this franchise to a very low single digit rate of erosion over the longer term.
And this in our opinion is a significant early win for a business that was experiencing double digit decline prior to the spin.
With that now I'd like to turn over the discussion to math Matt.
Thank you Kevin I'm pleased to go into further detail on our results for the third quarter not just because the performance was solid but also because we reached an important milestone in financial reporting this quarter.
Oregon on was a standalone entity in both the current and prior year periods, which means. This is the first earnings call that we can discuss performance with apples to apples comparability to the prior year period without being obstructed by the carve out basis of accounting that we needed to employ for pre spin off accounting periods.
And with that open or we will start the financial discussion on slide seven.
I'm showing this slide for two reasons first to highlight operational performance by geography, and second and really more important to provide a basis for understanding just how much organized results are subject to foreign exchange translation.
On an operational basis, our best performance in the third quarter came from the United States and Asia Pacific Japan regions. The.
The U S is an important market representing a quarter of our business. So the 6% growth in that market. During the quarter was meaningful and was primarily driven by growth in <unk> and also entresol and reflects us the two biosimilars that we offer in the United States.
On a constant currency basis, the <unk> region grew 13% during the quarter.
We continue to benefit in Japan, where generics since really since the start of the year have been having structural supply issues related to GMP performance and quality issues. Now this presents an opportunity for organ on we've been able to flex our manufacturing and supply chain capabilities to meet market demand.
We've also seen growth in southeast Asia in Thailand, and as Kevin mentioned, we shipped our first order of Marvel lines in Vietnam in the third quarter.
Our remaining regions were level with prior year during the quarter on a constant currency basis, we had very strong performance in China. During the third quarter of last year related to resupply of key products from long back orders. So it was a tough comparison point in China for established brands, but growth in fertility and and other women's health, namely Marvelon.
Offset the modest decline in established brands.
We're seeing strong demand for <unk> and la mirror, but that was offset by the phasing of an entre is on tender that we received in the third quarter of last year, but move to the second quarter of this year.
And you can we had good volume growth in Biosimilars and established brands, but that was offset with annualized pricing erosion and established brands in Europe .
As we think about foreign exchange other than the U S dollar, which represents about 30% of our revenue exposure. We have most exposure to the euro which is about 20% of our revenue the Chinese renminbi, which is about 15% and the Japanese yen, which is less than 10%.
But my main point here is that with about three quarters of our revenue outside the U S. Our portfolio faced a significant headwind from FX not unlike a lot of other multinational companies, but in our case it amounted to a full seven percentage point swing in revenue growth for the quarter, but unfortunately masked the.
<unk> growth in local currencies that we delivered.
Turning to slide eight which bridges our year over year quarterly revenue performance by key driver.
Revenue for the third quarter was approximately $1 5 billion down 4% as reported but up 3% at constant currency when compared to the third quarter of last year.
The components of the seven percentage point swing in revenue that I was referencing.
The impact of loss of exclusivity or low during the third quarter compared to last year was negligible in the first half of this year. The majority of low exposure in the portfolio was coming from Nuvaring, but that was countered this quarter by favorable volume demand in the United States and Nuvaring revenue actually grew modestly year over year in the.
Third quarter.
In addition, we didnt have any low impact and established brands this quarter.
The most significant eloise facing the portfolio washed out prior to the spin off and we expect only modest new low exposure going forward.
Now since the spin off in 2021, we have been expecting a generic entrant in the U S for delair that did not happen in 2021, and now looks very unlikely for the remainder of 2022.
Continuing to read across the waterfall chart the impact from volume based procurement in China was also negligible negligible in the third quarter, which is also the case year to date is the implementation of the next rounds of GBP had been delayed that said, we expect the <unk> implementation to resume in the fourth quarter and then it will primarily impact.
<unk> as a trial.
Moving across we saw an approximate $30 million impact coming from price in the third quarter, which is consistent with our expectation that we will see low single digit price erosion on a companywide basis and this is mostly coming from established brands, where our products are subject to mandatory price reductions in some markets.
We had good volume growth in the quarter that came mostly from our growth pillars, Nexplanon, particularly United States and Latin America Biosimilars in the U S respiratory and cardiovascular products in the <unk> region, and just overall growth in fertility.
And finally foreign exchange translation continues to be a significant headwind for us as I introduced on the last slide and here you can see the translation impact of approximately $100 million on the top line.
Now, let's take a look at our performance by franchise and we'll start with women's health on slide nine we.
We had very strong growth in the United States in women's health during the quarter driven by 34% growth in <unk> we.
We did have a favorable comp in <unk> in the third quarter of last year as annual patient well visits were depressed and there was also a tender in Mexico that would normally at the third quarter, but moved into the fourth quarter of last year.
In addition to volume growth. Our Q3 2022 performance also reflects our ability to secure modest price increase in nexplanon, but that had a lesser impact relative to volume.
And as Kevin mentioned, we also saw a double digit growth in fertility. This quarter, we had better performance than Nuvaring and other women's health, which reflects the re acquisition of Marvelon rights in China.
Turning to Biosimilars on slide 10, Biosimilars declined 7% as reported and 4% ex FX in the quarter, which really reflects timing of revenues year to date Biosimilars has grown revenues double digits and is on track to grow double digits for the full year, what we're seeing here in this quarter is the tendency.
For the for the Biosimilars business to be lumpy due to timing of tenders.
Both <unk> and <unk> performed strongly in the U S. During the quarter and overall the U S. Biosimilars business was up 23% on a constant currency basis, but year over year tender phasing in in this case in Brazil for <unk> offset those increases in the quarter.
Turning to established brands on slide 11.
With close to 90% of the revenue and established brands coming from outside the U S. FX translation impacts are most prevalent in this franchise rare.
Revenue for established brands was down 11% as reported and down 2% ex FX in the third quarter we.
We've seen very strong year to date performance with growth with revenue up 6% at constant currency.
Given the strong nine months performance, we now expect that revenue for established brands will land and modestly positive territory for full year 2022 on a constant currency basis.
The question we received most from investors is what can be established branch franchise due next year and over the longer term.
So since the spinoff we've said we could manage this business to very low single digit erosion on the top line at constant currency.
We think we can deliver at least that performance over the intermediate term and has three reasons why we believe this first our actual revenue performance in the first five quarters since the spinoff has exceeded our expectations.
More than half of our established brands portfolio will have already gone through <unk> in China by the end of this year.
And three there's very modest <unk> left in the portfolio.
So now turning to our income statement on slide 12, we've already discussed revenue. So we'll move down the P&L from gross profit were excluding from cost of goods sold purchase accounting amortization and one time items related to the spin off <unk>.
Making these straightforward adjustments in the third quarter of 2022 non-GAAP . Adjusted gross profit was 1.032 billion on revenues of $1 $53 7 billion.
Representing a gross margin of 67, 1%, which was up from 64, 9% in the third quarter of last year.
The year over year improvement in gross margins is primarily due to favorable product mix and a $24 million charge in 2021 related to our long term vendor supply contract conveyed as part of the spin off.
Adjusted EBITDA margin was 35, 5% in the third quarter of this year compared with 38, 2% in the third quarter of last year and just a quick reminder, that we've revised our presentation of adjusted EBITDA to conform with industry wide SEC guidance to include IP, R&D and milestone payments.
<unk> within any adjusted income report and in our case adjusted EBITDA margin. This quarter includes $10 million of acquired IP R&D and milestone.
Paired with $25 million of similar costs in the prior year period.
Higher selling and promotional costs as well as R&D spending associated with recent acquisitions of clinical stage assets contributed to the decline in adjusted EBITDA margin year over year.
As we as we have been communicating consistently since the spinoff expenses to develop new products to support commercial product launches and to build core capabilities are going to be drivers of our adjusted EBITDA margin in the intermediate term.
As we look at debt capitalization and leverage on slide 13 as of September 32022, we have debt of $8 $7 billion.
Netted against cash and cash equivalents of $500 million.
Our bank Covenant calculations provide for the add back of acquired IP R&D and milestones to our last 12 months EBIT calculation, which is how we have been presenting leverage ratios in prior slides exit on prior earnings calls now on that basis net leverage was about three six times as of September 30.
Recall that at the time of the spin off in 2021, we had a pro forma net leverage ratio of about 4.0 times and we said then that we were targeting a leverage ratio of less than three five times on a sustained basis. So we've made progress on leverage reduction, which has been aided by $200 million in vol.
And Terry prepayments of our U S term loan b since the spinoff.
Turning to free cash flow on slide 14.
Part of the Oregon on investment thesis for stakeholders is that the Standalone business generates significant free cash flow, we set the dividend at a rate that would imply that we expect organized to generate north of $1 billion of free cash flow per year and that basic math still holds the recency of the spin and related to.
<unk> have some payments to Merck coupled with unfavorable foreign exchange translation Obfuscates. This important characteristic of our business and our year to date free cash flow calculation. So on this slide I'm going to walk through a few of the issues most of which are transient in nature.
This simplified year to date free cash flow on this slide starts with $1 $7 billion of adjusted EBITDA, which as I mentioned earlier includes the impact of acquired IP R&D and milestones.
Biggest change relative to what we had expected at the start of the year is the working capital line item highlighted in Green and there are three components, making up this $764 million use of cash first is the timing of about $300 million of working capital build related to the spin off and separation from Merck.
We expected this figure to be built during the prior year period, but it has slid into 2022.
Second is an increase in normal course cash cycle working capital of about $250 million about half of that is related to intentional strategic growth in inventory, where it can drive revenue performance and our growth pillars, and that's mainly in Biosimilars and the completed acquisitions in women's health with the remainder in <unk>.
Line with volume growth across our businesses.
And the third driver is foreign exchange translation and the reporting impact there was about $160 million.
So the working capital build associated with the spend together with the FX impact has been significant year to date, we wouldn't expect items like these to be of this magnitude in future years.
Our capital.
Allocation priorities remain consistent with past communications, our first priority of course is servicing the dividend. Our second priority is organic growth, which would include lifecycle management opportunities for existing products within our portfolio supported by capital deployed in our manufacturing plants.
On the latter we expect to see annual Capex in the range of 3% to 4% of revenue on an ongoing basis, excluding separation costs, although we're very likely to finish below this level in 2022.
That should leave significant self generated cash flow for our third capital allocation priority, which is really a tie between execution of external growth plans to develop a portfolio of new product opportunities with an increased focus on immediately accretive or imminently accretive acquisitions, we will balance that against discretionary debt reduction.
We're committed to maintaining our double BBA to parent rating balancing debt reduction with capital deployed for externally source growth initiatives.
Turning to revenue guidance on slide 15 here, we bridge our expected revenue change year on year the impact of foreign exchange translation has increased throughout the year to where we now expect an approximate $400 million or an approximate 650 basis point headwind based on where spot rates are today.
Given where we are in the year, we're able to narrow our guidance range for full year 2022 revenue from six one to $6 3 billion to six 1% to $6 2 billion.
Consistent with the movements, we've seen in foreign exchange translation.
For LOE at this stage in the year, but generic do layers looking unlikely. So together with the recent favorability and Nuvaring, we expect low impact for 2022 will be about $25 million for the full year.
For <unk> in China, the implementation of around 7% eight had been delayed so again, we've not had any year to date impact from BBT. This year. However, the inclusion of <unk> as likely in the fourth quarter. So we're now forecasting just under $50 million of impact from GBP for the full year 2022.
We continue to expect about $150 million of price erosion in 2022 in line with historical pricing trends for global markets that we've been selling into for many years.
Our teams across the world are focused on improving profitability and delivering profitable growth you can see that in our estimates for price erosion those have actually improved by about $50 million from our original 2022 guidance back in February .
And for volume, we're tracking to approximately $550 million of growth for the full year, which has come down from the 6% to $700 million of growth since we last guided that's primarily related to two factors.
First given the protracted nature of Lockdowns in China, we've seen slower than anticipated recovery, particularly in the fertility clinics in the overall retail market and.
In spite of this transient headwind, we still feel very good about our business in China and in our ability to grow our business in China.
Second in order to meet emerging demand trends, we're seeing for certain established brands products, we've strategically aligned our supply priorities to more timely meet those demands and that has resulted in different shipments schedule for the fourth quarter that we anticipated in prior volume guidance.
The majority of our year over year volume increase is coming from our multiple growth pillars, Nexplanon biosimilars fertility, followed by favorable onetime items like the competitive issue in Japan and to a lesser extent recent business development activity.
We do expect net volume growth across our product portfolio and established brands as well, which is supported by our year to date results.
Turning to other guidance metrics on slide 16, as I mentioned were recasting our revenue range to incorporate the continued strength in the U S. Dollar. We're also tightening our estimates on depreciation and interest expense given where we are in the year.
The other range, we're modifying this quarter as for adjusted EBITDA margin to reflect the operational favorability, we've seen year to date. So we're adjusting upward the range accordingly from 32% to 34% to $33 five to 34, 5%.
That includes $107 million of acquired IP R&D year to date.
Taking the midpoint of our guidance that would imply second half margins EBITDA margins, just north of 30% area.
As we said last quarter second half 2022 margins are a directional indicator for what 2023 adjusted EBIT margins could look like in advance of organ on formally releasing 2023 guidance, which we will do when we report our full year results in February .
The movement in our EBITDA margin is a function of reinvestment in our business, primarily in new clinical programs, new commercial product launches and in our R&D and commercial capabilities that position the company very well to deliver sustained revenue growth in the future.
Wrapping up the financial discussion on a constant currency basis. The business has performed very well in the third quarter and nine months year to date really as we expected actually better than expected and established brands, which is over 60% of our total revenues and together with Biosimilars in women's health our guidance range implies annual revenue growth of.
3% to 5% on a constant currency basis, which is right, where we thought we would be.
At this point I will turn the call back to the operator for questions.
Okay.
At this time I would like to remind everyone in order to ask a question press Star and then the number one on your telephone keypad well pause for just a moment to come all the Q&A roster.
Okay.
Your first question comes from the line of Terence Flynn with Morgan Stanley . Your line is now open.
Great.
For taking the questions I guess two for me maybe.
Maybe Matt you can help us think about.
What your outlook is for China heading into 2023, you mentioned some of the variables you've seen here playing out over the last couple of quarters, but as you think about 'twenty three.
Are you thinking about.
About the growth outlook, there and then the second question I had is on your Biosimilar Humira had Lima.
Assuming you have had some initial conversations with U S payers at this point I know youre not launch until July but maybe just how are you thinking about second half of 'twenty three.
Terms of both share and then price point. Thank you.
Okay I'll take the first part of that question, which relates to China. So we expect to see growth in China in 2023, that's mainly coming from the strategic shifts that we've been executing from the hospital channel to the retail channel. We do expect <unk> will and we'll certainly be at par.
Play.
We'll limit the growth that we expect will but we do expect growth in China in 2023, So directionally I can I can give you that much and turns that going to I can address the second part of your question in regards to Biosimilars I personally met with a number of.
The larger pbms in the U S.
And.
I think that 2023, we will obviously be kind of a light ramp up year.
As people or pbms or kind of locking in some of the contracts for 'twenty three as we speak now.
And so I do believe that where you have closed systems like our government business VA large hmos like Kaiser that could be potentially more aggressive.
In terms of in terms of the switch, but I think in terms of overall on the <unk> side Youll see more of that business start to fold in in 'twenty four and then ultimately really open up in 'twenty five, but we feel very very good after discussing with those pbms that our product profile and are offering everything from the real world.
Evidenced in the low <unk>.
And hive citrate free concentrations that we have got coming plus they were very excited about obviously our pen device.
I keep using the term frictionless experience.
For many patients and so I think the general the general assumption is that what I'm hearing is that they will accept maybe too.
Best III, but probably more likely to biosimilars on formulary and ultimately I think we're in good shape when it comes to that.
Okay.
Okay.
We can take our next question from Australia.
Okay.
Your next question comes from the line of ammo rats at Evercore ISI.
Your line is now open.
Hi, guys. Thanks, so much for taking my questions maybe.
Maybe a couple of here if I may I wanted to this is one of your pipeline programs, which looked very interesting based on its prior data.
<unk> Brent.
But the pace of development really confuses me, especially since it looks like there's been almost no progress since you guys in licensed mid last year and my understanding is you're trying to file an IND.
But I'm more confused sort of over the course of 12 to 18 months of a 90 is not filed is there something more significant that's holding it up.
We understand it better.
And then secondly, just on the comments on Biosimilar Humira, you said it'll be like ramp up ERP be EMS are locking up contracts.
But it looks like the estimates and the street expectations are all over the place on some players there's as much as $2 billion plus in the Biosimilar Humira I think in your case, you're talking it down and Youre, implying more of a 2020 for 2025 and most investors read that as more of a sort of $3 million to $500 million type of opportunity could you just lay some parameters for us because I.
I feel like this is one of those line items that could get mis modeled especially in the context of the overall timeline you guys have thank you.
Thanks tumor I can start with the second part of your question and then I'll hand, it over to Sandy to address the issues that you brought up an ebook footprint.
In regards to the Biosimilars look it is going to be a kind of a lot of the us a lot of a lot of things growing up in there because it's hard to really understand right now because <unk> is still trying to develop their strategies.
And overall I think what what what we're guiding to is essentially what <unk> seen out there and you're right, we're guiding to a lower number versus the.
The $1 billion that you see out there I do think theres going to be some pretty aggressive discount discounting taking place obviously nothing on the on the level of our small molecule discounts that you see but obviously, but there will be some and I think because it's a pharmacy dispense product and it's the largest.
Biologic coming off patent there is a lot of questions. Obviously, you can you can imagine in that area, but again rumor we feel very good about where we are we've got we've checked all the boxes off.
A lot of the Pbms, we're talking to feel that 23 will be a kind of a.
Light take off in terms of the fact that the originator will still be there obviously in full force.
But then 'twenty four it will start to open up in 'twenty five.
And be much more aggressive in it.
And over the years Youll see price erosion starting to hit we feel very good about the consensus thats been put out there on the AWN had Lima.
It is going to be a successful product for us and we'll have to see what the 2023 brings but I do think it'll be a light glide path and then ultimately it will open up in 'twenty four 'twenty five sandy sure. Thanks for the question. So as you probably recall, we brought over the IBO key trends at that.
<unk> of <unk>.
To spend and to your point.
<unk> initially.
T study against <unk> as an add on therapy in select European and other countries. The preclinical data package that was put together by a D that satisfy the individual country requirements for the clinical trial application. However, we anticipated would not satisfy that requirement.
Past that now.
Mr of the FDA in order to get a move forward on indeed submission. Therefore, it right. After we acquired the asset we started out contracting and doing our preclinical work with our providers and it has taken a little bit longer in the sense in the contracting are just starting up at the company.
But we're fully online and we have the initial initial results from many of the studies, we've already had a pre IND meeting, where we discussed not just the preclinical data for our development plan initially and we had a very robust and our interaction with the FDA to think about that clinical development program ahead.
So we are anticipating after the finalization of the data readout in the study report that we will be able to file the IND and passed muster early in 2023.
Yes.
Thank you next question. Thanks framework. Thanks. Your next question comes from the line of.
David <unk> with Piper Sandler Your line is now open.
So just.
One question on Nexplanon in one established brands so on next Malone.
I'm trying to get a better sense for how we should think about adoption growth and a more normalized post pandemic environment and more specifically what portion of Obgyns, who have already been trained and how much remaining is out there too.
Train.
Going forward. So that's number one and then on established brands you cited cardio and respiratory is as being particularly resilient I'm just wondering how sticky those products are and even just beyond those therapeutic verticals.
Thinking about these ex U S markets, what's your view on.
I guess for lack of a better term brand loyalty relative stickiness.
These products going forward. Thanks.
Sure. Thank you David for the questions. Let me start with next one on.
I do believe that the pandemic clearly as we've seen has created a lot of a lot of confusion in the market I mean, we still see a 25% reduction in regards to women's health visits.
I have never bounce back.
Versus pre pre pandemic.
And so pre pandemic levels, so I would say to you that.
It is it is a slow moving process in terms of getting everyone back that kind of issue that needs to be addressed obviously.
But when you come when you speak about long acting reversible contraceptives and Exelon is garen gaining share because what we do is what we see as the iuds are losing favor we'd see that obviously, it's hard to get that from our <unk> data because its a buy and bill model, but nevertheless, we see that from other companies report out that.
Large IUD manufacturers are seeing declines in that business, but we continue to see increases I see we see increases in physician demand quarter by quarter, We had a really strong quarter. As you said as I mentioned earlier in terms of the third quarter with 26% growth in the U S alone and we do.
See that we're starting to gain share there. So I do agree with you that some of the noise is going to have to come out of the system and I believe as we go forward in 2023, and 2024 youre going to start to see more stickiness as to use your vernacular in terms of nexplanon kind of really getting.
And more into the mainstream of a lot of obgyns using that product because there is a demand I mean, when you start to think about it what is the need the need is the fact that we've got nearly a 45% unintended pregnancy rate in the U S and the fact that people are little fact that people don't really recognized as a 40% of those unintended pregnancies patients where women were.
Using some form of contraception. So clearly shows you they need more real world high efficacy and Thats where <unk>.
It's really uncertain forget and you've got the <unk>.
Among the highest if not the highest level of protection against unintended pregnancy. So I do believe that profile will gain more traction as we start to see more women come back and ultimately the things that we're doing around.
Clinical training programs as well as direct to consumer advertisements and things that we're doing with that nature.
In regards to established brands I do believe the ex U S business is sticky you see that.
You see in China for example, our business continues to grow in spite of in spite of <unk>.
Pvp rounds, as well as the Lockdowns, we still still still see retail growth, we see e-commerce growth I do believe that in many of these markets, especially in the emerging markets you see a lot of brand loyalty, especially.
Around cardiovascular and respiratory products, our respiratory products, especially in markets that have very high seasonal allergy seasons.
Do do extremely well and so products like <unk> X products like single there continue to do very well and are very robustly accepted and people pay out of pocket for that and at the same time and many of these emerging markets. They want a reliable high quality supplier that has good science, good manufacturing knowhow and people.
Feel very very tied to their brands.
So I do believe going forward as I mentioned that we will see very very low single digit erosion, they're going to be some years like this year, where we see a lot of upside in certain markets, where we see growth and it's been pretty robust growth for established brands, which is unique youll be other years, where you get very low single digit erosion to get other years, where it's flat so overall.
Though for the long term I think it's a really good thing to say about this business, which is two thirds of our business in large part of our free cash flow.
Thanks, Dave.
Thank you.
Your next question comes from Chris Scott with J P. Morgan.
Hi, This is a cat arena on for Chris. Thank you so much for taking our questions.
Question is on margins can you just help us or rather elaborate on some of the drivers of the better than expected kind of margin trends. This year, how much of that is delayed spend versus something that you can keep carryover to future periods and then you talked a little bit about 2023, but more wondering should we thinking about 22023, that's kind of a floor for margins.
Or is that kind of potential for another step up in operating costs as we think about 2024 or 2025. Thank you so much.
Yeah, so the better than expected performance on.
Margins. This year is a function of a few things you can't just tie it to one driver, but what we have seen is better than expected price performance right price still went down across the portfolio, but not by as much as we had thought at the beginning of the year.
Our product mix.
Ben.
Little bit more favorable than we thought and our overall manufacturing performance in the plants.
Now in terms of margins going forward I think.
Sort of.
Early directional indicator that we gave about margins.
Half margins being a directional indicator for 2023 encompasses everything we know at this time about that.
The amalgamation of forces that will be impacting us in 2023, so in that in that directional indicator that includes at least to the extent we know now right. We're in the middle of our budgeting process for the company, which has yet to conclude but product mix will always be one of the most significant drivers of our margins.
Year on year, what we know about that now is baked into that directional indication.
The margin up.
Basis, we continue to improve productivity in our manufacturing plants.
What we do expect to see some hits on of course is inflation for.
For next year that is impacting our numbers this year, but to a lesser extent, we expect to see a bigger impact of that next year and once again, we've got the steady drumbeat year over year of price pressure across the portfolio given the age of the products, but all of that is is.
It has been considered in the directional indicator that I provided.
Great. Thank you so much.
Okay.
Your next question comes from the line of Chris.
<unk> <unk> with Goldman Sachs. Your line is now open.
Hi, This is Dan on for Chris Thanks for taking our questions. I guess first on had Lima could you guys maybe talk about how impactful you see interchange ability being once you ultimately received at both being on formulary and commercial area commercially or instead of Biosimilars and then second on capital allocation you guys have.
Scott, maybe more potentially near term accretive deals could you maybe just again.
Again kind of the current thinking on views across segments and areas of focus on women's health.
Sure.
I can address the first question on Biosimilars on his Lima in my discussions with all the Pbms that I've interacted with a new large ones interchange ability does not come up as a.
As a key point.
Is something that I think they'd like to see that is underway and we will have our interchange ability indication likely in the 2024 timeframe.
So that's fine that's kind of check the box there theyre more focused on a number of other issues number. One is do you have the manufacturing capability to make sure that whatever order because it's large volumes will be met do you have a pen again I use the term frictionless experience.
Look you don't want they don't want to give their health care providers, a reason to move off because patients don't have the ability to be able to inject seamlessly in and so we feel really good about the device that Samsung has put forward for us.
Do you have real world evidence.
Because we don't want to be the first country that you actually saw.
Sell in providing commercialize your product and then finally do you have the high concentrations, which are free and the low concentration because there are some customers approximately about 20% of customers in the U S. Due around the 20% of the business in the U S is moving towards a low concentration form so both of them, we've got that box as well.
Checked off so we're feeling very comfortable with our position in terms of the profile.
And regarding capital allocation.
What we have been seeking to do since the spin really is to bring balance.
And our capital allocation between innovative assets that address large.
Areas of unmet needs in women's health, where the where the <unk>.
Commercial opportunity is also strong those tend to be longer duration product development cycles.
And so we've been trying to match that.
With either.
<unk> accretive or imminently accretive deals.
That can effectively keep the business.
And the more and the operating margin for posting within a range that you know, it's just representative of a well run business. So we've recently put in some longer.
Some more early phase assets and so as we think about balance that would suggest that some of the next deployments that we do.
Should be either meet immediately accretive or imminently accretive once again just to bring balance to the overall program.
Your next question comes from the line of Jay.
Jason Garrett Barry CEO .
Your line is now open.
Oh, Hey, good morning, Thanks for taking my questions.
I just wanted to come back one question on <unk>.
Humira.
You mentioned that Pbms are locking in contracts now we heard from Teva earlier this morning.
Part of the settlement agreement you kind of like contract when you launch so I'm just trying to reconcile those.
Scrapping viewpoints and ultimately another thing I was curious about your one month order of entry advantage versus the sort of next wave of Biosimilars I realize its kind of a small time differential but I'm wondering.
Anticly does potentially give you a leg up that you think investors might be under appreciating and that could be potentially from a contracting perspective.
An advantage that could be material.
Thanks for the question, Jason what I was saying at least in my script and ultimately in the discussion with them or is the fact that.
Pbms are now kind of looking at their business for 2023, they're not kind of locking it in and Youre right. I mean, what Teva said earlier is correct that we can't start to really negotiate and contract based on the agreement that we have without them.
But nevertheless, what I will tell you is the fact that.
We believe that 'twenty three.
The glide the ramp kind of the ramp up will not be as dramatic because its youre coming in half of the year.
By that time, the contracts will obviously be in place.
Origination or will be on formulary, obviously, there will be kind of a.
Fight in terms of.
Getting on formularies, and so theres a lot of that kind of tactical activity instead of activities, but I do believe that 24 will be a much what I'm understanding from all the pbms that I talked to as well as <unk>.
Government officials and government business like the VA as well as the Kaiser system.
Those closed systems will move faster to replace and potentially have.
Business switched over more than a aggressive fashion PBS will take their time and ultimately that's what I'm signaling is that it's going to be more of a 'twenty four and 'twenty five timeline, where you really start to see a lot of movement, we believe away from the originator.
Essentially what happens to price in the marketplace.
Okay fair enough. Thanks, so much.
Yeah.
Operator, I think our last question.
Your last question comes from Greg Fraser with <unk> Securities. Your line is now open.
Good morning, Thanks for taking the questions. My first one is on the large category curious how much of the pressure on Ied demand had been tied to temporary COVID-19 related headwinds versus drivers that could be more durable overtime.
And then on established brands when you think about 2023 and beyond where do you still have exposure to.
<unk> you comment on longer term growth.
Should we expect greater pressure on 2023 sale tightened of edp versus future years. Thank you.
Yeah, So Greg let me address.
So some of those questions. So in regards to.
Your second question regards to <unk>, we do believe that.
The Pvp round seven will happen in November of this year.
Month, and essentially one of our cardiovascular products <unk> will be on that list for around seven.
But by the end of 2023, we see that more than three quarters of our business.
We will have gone through the volume based procurement process.
And so.
You offset that with the growth that we have right now we're more almost 50% of our business is going through the retail channel and more and more of that business is now starting to go through the E. Commerce channel, we will still see basically China with a high single digit growth opportunity and potential going forward into the 2023 2024 more <unk>.
24 timeframe, where we see that there is opportunities to actually grow the business.
Sorry, your first question.
UBS on the stickiness of Ieds and what's happening in regards to the.
The pandemic.
It's hard to look I can't answer the question in terms of what physicians and patients are thinking in regards to their acceptability of iuds, but I can say that.
The unique thing about Nexplanon is it literally takes one or two minutes to insert and it takes the same amount of time to remove.
It is much more convenient in terms of being able to use it as a long acting reversible contraceptive that can fit in so many different settings.
In addition to that it has the same basic efficacy as an IUD does.
The difference is that you know you're talking about a product.
Got it.
<unk> currently works with efficacy for three years, we're working on a five year extension. So that means we'll have efficacy for duration for five years that will be launched in probably the 2025 timeframe. So we do see a long and productive runway for us for <unk>, and we do see more and more patients coming online and higher demand.
<unk> is a reasonable alternative when a woman wants to have a long acting reversible contraceptive and currently that Theres all the signals all the signs that we see in the marketplace, especially in the U S and ex U S, which is growing actually even faster than the U S is that it is a methodology of form of contraception that people are getting much more.
<unk> two it because again back to the basic principle in our hands, we've been able to give it the right type of attention the right type of senior management attention. The resourcing to ultimately kickstart and get that business to be a $1 billion business in the very near future. It will be our first billion dollar blockbuster for an excellent on probably in the 2020 for 2025 timeframe.
Yeah.
Thank you.
Yes.
Yeah.
So I think that Kevin asked a couple of closing yes, just in closing for all those thanks for the questions by the way just in closing.
Oregon on has really had a strong third quarter with all three franchises continuing to make really important contributions were building a business as you all can see that as sustainable and it's a sustainable growing concern our track record to date supports what we have said from the very beginning of the spin that in our hands. This portfolio of assets can generate.
<unk> sustainable growth.
So I want to thank you for joining us today, and we look forward to continuing to communicate our progress with all of you is that as time permits. Thank you very much.
Ladies and gentlemen. This concludes today's call. Thank you for attending you may now disconnect.
Yeah.
Okay.
[music].